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Abstract 
Purpose Neuroblastoma is an embryonic solid tumor derived from the progenitors of the sympathetic 
nervous system. More than half of the patients developed metastatic disease at the time of initial 
diagnosis and had poor outcome with current therapeutic approaches. In recent years, some obligate 
and facultative anaerobic bacteria were reported to target the hypoxic and necrotic region of solid 
tumor models and caused tumor regression. We recently successfully constructed an “obligate” 
anaerobic Salmonella strain YB1 that was applied in breast cancer nude mice model by us. Here, we 
report the application of YB1 in neuroblastoma treatment. 
Methods The anti-cancer effect and side-effects of YB1 was examined in both in vitro and in vivo 
experiment. Previous established orthotopic neuroblastoma SCID/beige murine model using 
SK-NLP/luciferase cell line was adopted. 
Results In vitro, YB1 induced apoptosis for up to 31.4% of the neuroblastoma cells under anaerobic 
condition, three times more than that under aerobic condition (10.9%). The expression of both Toll like 
Receptor 4 and 5 (TLR4 and TLR5) in cancer cells were significantly up-regulated (p<0.05, p<0.01 
respectively) after the treatment of YB1 under anaerobic condition. In mouse model, YB1 preferentially 
accumulated inside the core of the tumors, rather than in normal tissues as our previous reported. This 
is suggestive of the hypoxic nature of tumor core. Tumor growth was significantly retarded in YB1 
treatment group (n=6, P<0.01). Furthermore, there was no long-term organ damage noted in all the 
organs examined including heart, lung, liver, spleen and brain in the YB1 treated mice.  
Conclusion The genetic modified Salmonella strain YB1 is a promising anti-tumor strategy against the 
tumor bulk for neuroblastoma. Future study can be extended to other common cancer types to verify 
the relative efficacy on different neoplastic cells. 
Key words: neuroblastoma, xenograft, Salmonella, hypoxia, target-killing. 
Introduction 
Neuroblastoma is one of the most common 
extra-cranial solid tumors found in infancy and early 
childhood, which is diagnosed at a median age of 
about 17 months. It is known that early and advanced 
stage neuroblastoma behave differently and they are 
two biologically different types of tumors. However, 
majority of the neuroblastoma found after 
18-month-old belongs to the advanced stage with 
metastasis. They have very poor prognosis even with 
current multi-modality therapeutic approach. 
Neuroblastoma can arise from anywhere along the 
sympathetic nervous system, but majority of them 
have the primary tumor in the adrenal medulla [1]. To 
simulate such natural microenvironment, 
intra-adrenal orthotopic xenograft neuroblastoma 
mouse model is a valuable tool in improving our 
 
Ivyspring  
International Publisher 
 Journal of Cancer 2017, Vol. 8 
 
http://www.jcancer.org 
1610 
understanding and control of neuroblastoma. It 
allows tumor growth and metastasis to take place and 
makes it convenient, precise and reliable for drugs 
experiment in vivo [2, 3]. Research findings suggested 
that neuroblastoma cancer stem cells and the cancer 
niche are thriving better in hypoxic 
microenvironment and they are resistant to most 
treatments. It is because the therapeutic agents or 
cytotoxic drugs cannot penetrate the poorly 
vascularized, hypoxic regions of the tumors, therefore 
leaving these sites untreated [4, 5].  
This prompted researchers to search for an 
alternative treatment strategy. An ideal tumor 
therapy vector should be specifically present in tumor 
hypoxic regions, while absent in normal tissues. This 
kind of vector may help to target the most resistant 
area of the tumor. Fortunately, facultative anaerobes, 
such as Salmonella typhimurium, can target both small 
and large tumors and reduce tumor size [6]. While 
wild type Salmonella strains may shrink tumors, their 
natural pathological virulence may result in the death 
of the host [7]. We recently engineered an “obligate” 
anaerobic Salmonella strain YB1 [8]. This strain was 
derived from a vaccine strain SL7207. It been reported 
to be an anticancer agent [9-13]. However, it is lethal if 
injected intravenously even though SL7207 is aroA 
defective [14]. In YB1, the essential gene asd has been 
genetically engineered to be controlled by hypoxia 
conditioned promoter. The asd gene is responsible for 
the synthesis of diaminopimelic acid (DAP), which is 
an essential component of the cell wall in 
gram-negative bacteria. Deficiency of DAP will lead 
to lysis of the bacterium, unless extrinsic DAP is 
supplied by the environment. The YB1 can only 
survive under hypoxic condition (less than 0.5% 
oxygen) without additional DAP [8]. The normal 
functions of this bacterium are not compromised by 
the deletion or mutation of any of its genes. The 
anti-tumor effect of YB1 in nude has been tested in 
mice breast tumor and neuroblastoma model by our 
group [8, 15]. In normal tissues under aerobic 
conditions, since asd is not expressed, YB1 are rapidly 
eliminated. In tumor, we further found that YB1 
accumulated inside hypoxic region and caused tumor 
regression [8].  
In this study, we attempt to investigate the 
tumor-targeting and potential tumor-repression effect 
of Salmonella YB1 against neuroblastoma. The possible 
association of apoptosis and TLRs genes expression 
was determined. The potential toxic effect to the 
normal tissues induced by either the genetic modified 
YB1 or the original Salmonella strain SL7207 on 
orthotopic SCID/beige mice bearing neruroblastoma 
was evaluated.  
Materials and Methods 
Bacterial strains, animals, cell lines, reagents, 
primers and chemicals 
Salmonella typhimurium strain SL7207 was 
kindly provided by Dr. Stocker [14] . The culture of 
SL7207 and YB1 was described previously [8]. 
Six-week-old male SCID/beige mice were purchased 
from the Laboratory Animal Unit of The University of 
Hong Kong. The research protocols were approved by 
the Committee on the Use of Live Animals in 
Teaching and Research of the University of Hong 
Kong (CULATR 2360-11) with the related animal 
license issued by the local Department of Health. The 
gene transfected neuroblastoma cell line 
SK-NLP/luciferase were cultured in Dulbecco's 
modified Eagle medium (DMEM; Invitrogen, 
Carlsbad, CA), containing 1000μg/ml G418 (Roche, 
Mannheim, Germany), 10% fetal bovine serum (FBS; 
Hyclone, Logan, UT), 100 U/mL penicillin, 100 
mg/mL streptomycin, and 2 mM L-glutamine 
(Invitrogen, New York, USA). Cultures were 
maintained at 37°C in a humidified atmosphere 
containing 5% CO2. Luciferin, 0.05% trypsin with 
25mM EDTA, Superscript II reverse transcriptase and 
DNase I were all bought from Invitrogen (New York, 
USA). Matrix and Annexin V were purchased from 
BD company (San Diego, USA). SYBR® Green PCR 
Master Mix kit was bought from Applied Biosystems 
(Warrington, UK). AllPrep® RNA Mini kit was 
purchased from QIAGEN (Hilden, Germany). 
Primers were synthesized by Integrated DNA 
Technologies (Iowa, USA). Rabbit anti-Salmonella 
antibody, mouse anti-TLR4 and 5 monoclonal 
antibodies and horseradish peroxidase conjugated 
secondary antibody were from Abcam (Cambridge, 
UK). DAB solution was from DACO (Tokyo, Japan). 
Anaerobic jar was from Mitsubishi Gas Chemical 
Company (Tokyo, Japan). The 3600M021-Metabolic 
cages were bought from Tecniplast Company 
(Buguggiate, Italy). Meloxicam was bought from 
Boehringer Ingelheim (Auckland, New Zealand). 
Chemicals were from Sigma (St. Louis, USA). 
Antibiotic stocking solutions were prepared as 
follows: Chloramphenicol, 25 mg/ml in methanol; 
Ampicillin, 100 mg/ml; Gentamycin, 50 mg/ml. 
Strains culture were supplied with 50 µg/ml DAP 
where noted.  
Salmonella invasion of neuroblastoma cells in 
vitro 
Salmonella and SK-NLP/luciferase cells were 
prepared and co-cultured at a ratio of 500:1 for 2 
hours under anaerobic or aerobic conditions. The cells 
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were then washed with PBS and cultured in 
gentamycin supplemented medium for 20 minutes to 
kill extracellular bacteria, then washed with PBS and 
added the medium with 100 μg/ml gentamycin to kill 
the residual bacteria. 24 hours later, tumor cells 
apoptosis induced by bacteria under aerobic and 
anaerobic conditions were detected by annexin V 
assay according to manufacturer’s instructions 
through flow cytometry. 
Total cellular RNA was extracted from cultured 
cells using AllPrep® RNA Mini kit according to the 
manufacturer's instructions. Reverse transcription 
was performed on the DNase I-treated RNA using 
Superscript II reverse transcriptase according to the 
manufacturer's recommendation. The cDNA that was 
synthesized was subjected to PCR amplification, and 
the PCR product was quantified by real-time PCR 
using the SYBR® Green PCR Master Mix. The primers 
that were used are shown in Table 1. The β-actin gene 
was amplified as an internal control. 
 
Table 1. DNA sequences of primers used in quantitative PCR 
analysis 
Gene Sequence 
β-actin F: 5'-CCGTCTTCCCCTCCATCGT-3' 
R: 5'-ACTTCAGGGTGAGGATGCC-3' 
TLR4 F:5'-AGAGTTTCCTGCAATGGATCAAG-3'  
R: 5'-TTATCTGAAGGTGTTGCACATTCC-3' 
TLR5 F: 5'- GGCTTAATCACACCAATGTCACTATAG-3'  
R: 5'- TTAAGACTTCCTCTTCATCACAACCTT-3' 
F, forward primer; R, reverse primer. 
 
Establishment of orthotopic neuroblastoma 
SCID/beige murine model [15] 
6-week SCID/beige male mice were inoculated 
with 0.2×106 SK-NLP/luciferase cells through 
intra-adrenal injection under the conditions of 
surgical microscope and anesthesia. Animals were 
anesthetized by intra-peritoneal administration of 100 
mg/kg pentobarbital. Subsequently, fur on the left 
side of the body between the fore and hind legs was 
clipped and prepared with alcohol and betadine. An 
incision was made over the left retro-peritoneal space 
to expose the left adrenal gland, and 10 μl matrix 
containing 0.2×106 neuroblastoma cells were injected 
into the gland with a disposable 29G needle attached 
to a 300 μl syringe. The incision was sutured with 5-0 
dexon. The animals were allowed to completely 
recover from anesthesia before being returned to the 
cage. After surgery, the meloxicam in drinking water 
was administered to minimize the pain at a dose of 
0.3mg/kg, 24 hourly for 3 days. Two weeks after the 
surgery, the tumor development was monitored 
under In Vivo Imaging System (IVIS, Xenogen IVIS 
100).  
Target neuroblastoma with Salmonella YB1 in 
orthotopic murine model and side-effects 
observation 
To measure the targeting and therapeutic effect 
of bacterial inoculation on orthotopic neuroblastoma 
murine model, three groups of mice (n=6) were 
treated with either YB1 5×107 Colony Forming Units 
(CFU) /mouse, SL7207 5×107 CFU /mouse or PBS 
with volume of 100 µl injected through the tail vein. 
Tumor growth was detected by Xenogen IVIS 100 two 
weeks after the treatment. Survival rate and body 
weight were recorded every 2 days. To measure the 
bacterial distribution after tail vein injection, mice 
were sacrificed and tissues were weighed, 
homogenized, serially diluted in PBS and plated with 
the chloramphenicol and DAP. CFU were counted 
after two days’ culture. To observe the side-effect, YB1 
(5×107 CFU/mouse) and SL7207 (5×107 CFU/mouse) 
were also injected through tail vein to 6 SCID health 
mice, respectively. Organs were harvested and feces 
and urine were collected by metabolic cages. The 
presence of bacteria in different organs was 
determined. 
Immunohistochemical analysis  
Bacteria and PBS treated tumor bearing mice 
were injected with overdose pentobarbital for 
euthanasia. Tissues were removed from these mice 
and immediately fixed in 4% paraformaldehyde, 
paraffin embedded and sectioned. Salmonella was 
detected by rabbit anti-Salmonella antibody. TLR4 and 
5 was detected by mouse anti-TLR4 and 5 monoclonal 
antibodies. Bound primary antibody was detected 
using horseradish peroxidase conjugated secondary 
antibody which then developed in DAB solution. 
Pictures were taken under a light microscope.  
Statistical analysis 
The unpaired, two-tailed Student t test was used 
to determine differences between groups for the 
comparisons of Quantitative-PCR, tumor weight and 
CFU counts of salmonella YB1 using SPSS computer 
software (SPSS). Any P-value less than 0.05 is 
regarded as statistically significant. 
Results 
Invasion of neuroblastoma cells by YB1 in vitro 
Neuroblastoma cell line SK-NLP/luciferase 
samples were co-cultured with YB1 or SL7207 under 
anaerobic or aerobic conditions. After removal of 
extracellular bacteria and overnight culture, the 
apoptotic rate of SK-NLP/luciferase cells in anaerobic 
conditions treated with each of the bacteria was 
assessed by annexin V assay. A significant increase in 
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the number of apoptotic cells was noted in both YB1 
(31.4%) and SL7207 treated groups (29.1%) when 
compared to negative control (1.02%) under anaerobic 
condition. However, under aerobic conditions, the 
YB1 showed much less cytotoxic effect to the cancer 
cells (10.8%), as compared to the 27.2% apoptosis of 
SL7207 treated cells (Fig. 1.), this result is consistent 
with our previous report in breast cancer model [8]. 
Accumulation of YB1 in tumor and normal 
tissues in vivo 
The YB1 distribution in tumor and normal 
tissues were determined 2 weeks after treatment. In 
tumors, YB1 was found to present in tumor with 
about 1.14×108 CFU/gram. In hearts, spleens and 
livers, YB1 was found to be 6.38×104, 9.81×103 and 
3.73×103 CFU/gram respectively (Fig. 2A). No 
bacteria were found in brain, lung, kidney, or blood. 
Immunohistochemical staining of sections of tumor, 
heart, liver and spleen confirmed the distribution of 
Salmonella bacteria in these tissues (Fig. 2B). There was 
some parenchymal infiltration in the liver but the 
distribution in the tumor was more diffused and 
extensive.  
 
 
Figure 1. The in vitro flow cytometry results of the annexin V assay after the co-culture with the 2 strains of Salmonella under the anaerobic and aerobic conditions. 
YB1 induced 3 folds higher apoptosis in anaerobic than in aerobic condition (31.4% vs 10.9%). Such differential effect was not noted in SL7207 treated cells. In addition, 
the differential killing effect between YB1 and SL7202 under anaerobic condition was not significantly different in the in vitro short term culture setting.  
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Figure 2. Accumulation of YB1 in tumor and normal tissues in vivo. A, 
Preferential accumulation of YB1 in the orthotopic tumors from mice 
administered systemically. SCID/beige mice bearing orthotopic 
SK-NLP/luciferase tumors were injected through tail vein with YB1 (5×107 
CFU) at day 14. The CFU amounts of accumulated YB1 (means ± SD, n =6) in 
the tumors, hearts, livers, and spleens were determined at day 28. ***P < 0.01. 
B, The immunohistochemical staining analysis of YB1 distribution. After 2 
weeks’ treatment with YB1, SCID/beige mice were euthanized and YB1 
accumulation in tumors, hearts, livers and spleens were assessed in tissue 
sections by immuno-staining (brown color pointed with red arrow). The left 
panel was YB1 treated group, the right panel was control group. 
Observation of the side-effects  
The mice inoculated with 5×107 SL7207 started to 
die on day 3. On day 8, all mice were killed because of 
infection. The CFU from the feces was 
2.98±2.15×105/g (n=6), and negative from urine in 
SL7207 treated mice. However, the mice injected with 
YB1 were all alive and active till to the end point of 
the experiment, and there was no bacteria detected 
either from feces or from urine. For the YB1 treated 
group, it showed that there was significant initial 
body weight loss when compared to the non-bacterial 
treated control (p values were shown in Fig.3). This 
might be due to some underlying toxic effect of the 
bacteria, especially in the early phase. The body 
weight started to recover after 6 days treatment (Fig. 
3).  
YB1 inhibited neuroblastoma growth in vivo 
As YB1 invaded SK-NLP/luciferase 
neuroblastoma cells in vitro causing cell apoptosis, its 
in vivo therapeutic effect was evaluated. Tumor sizes 
and growth were monitored by using a Xongen IVIS 
100. The data showed that tumor growth in YB1 
treated mice was significantly retarded compared 
with PBS treated mice (p= 0.0094) (Fig. 4A, B, C and 
D). No antitumor effect could be detected at Day 14 in 
SL7207 treated mice since all mice died between day 3 
and 8.  
The expression of TLR4 and 5 under the 
invasion of YB1 and SL7207 
Quantitative-PCR revealed that all TLR4 and 5 
were up-regulated after bacterial invasion. TLR4 gene 
expression was significantly higher after treatment 
with YB1 and SL7207 under anaerobic conditions than 
under aerobic conditions. The p values were 0.017 and 
0.041 respectively and the p values of TLR5 gene were 
p=0.001 and p=0.04 respectively (Fig. 5A). The 
experiment was performed in triplicate. In the tumor 
mass, the expression of TLR4 and 5 were also higher 
in YB1 treated group than control group from the 
results of the immunohistochemical staining (Fig. 5B, 
C, D and E). 
Discussion 
Neuroblastoma derived from aberrant 
sympathetic nervous system development. Due to the 
differences in the underlying genetic involvement, it 
exhibits diverse clinical behaviors. Some may 
spontaneously regress, while the aggressive forms in 
older children still account for a significant proportion 
of morbidity and mortality in children with cancers. 
Neuroblastoma represents for around 8% to 10% of all 
childhood cancers but takes up approximately 15% 
share of cancer deaths in children [16]. Advanced 
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stage tumors often infiltrate local organ structures, 
wrapping around nerves and vessels and are 
unresectable with extremely poor outcome [17-19]. 
Despite recent advances on diagnosis and therapy, 
50% to 60% of patients with high-risk neuroblastoma 
relapse, and to date there are no curative salvage 
treatment regimens available [20]. Current treatment 
for neuroblastoma included surgical resection, 
chemotherapy, radiotherapy, and biologic therapy 
such as isotretinoin (cis-RA), anti-GD2 
immunotherapy (3F8 or Ch14.18 and Ch14.18/CHO) 
[21-26]. 
To be able to sustain continuous growth, solid 
tumors need to induce neovascularization to ensure 
sufficient supply of oxygen and nutrients. However, 
tumor-induced vessels are often malformed, resulting 
in inadequate blood circulation and accompanying 
hypoxia [27, 28]. Hypoxia provokes a general 
adaptive response in neuroblastoma cells and those 
survived show loss of the neuronal phenotype, gains 
of stem-cell characteristics such as self-renewal and 
tumor propagation in vivo.  
This cell subpopulation often resides in the core 
of the solid tumor, which is hypoxic, and was found 
to have the characteristics of cancer stem cells. 
Hypoxia promotes expression of genes that mediate 
cell survival, growth, and resistance to treatment. The 
genes included HIF-1a, HIF-2a, glucose transporter 3 
(GLUT3), vascular endothelial growth factor (VEGF), 
IGF-1, IGF-2, insulin receptors, neuropilin-1 (NRP1), 
metallothioneins, MT2A and MT1H et al. [4]. All these 
make these special neuroblastoma cells adapted to 
hypoxic environment more resistant to therapy since 
they have a lower proliferation rate; are exposed to 
lower concentration of cytotoxic drugs which rely on 
delivery via the circulation; and are less sensitive to 
radiation therapy due to the resistant to oxidative 
damage. 
In order to mimic the generation and 
microenvironment of human neuroblastoma, we 
utilized the fluorescent orthotopic xenograft mouse 
model of human neuroblastoma. The tumor was 
generated by direct adrenal injection, because more 
than 80% of human neuroblastoma arises from 
adrenal gland and adrenal injection can mimic the 
microenvironment of neuroblastoma [3]. This animal 
model can be directly visualized with the expressed 
gene of luciferase in the SK-NLP cells, and is a 
non-invasive and reliable way to assess the tumor 
progression and metastatic potential of 
neuroblastoma. In this model, we were able to achieve 
100% tumor engraftment rate in the SCID/beige mice, 
and they could all be visually monitored under the 
Xenogen IVIS 100. 
Genetic modified anaerobic bacteria provide an 
alternative treatment strategy in cancer therapy due to 
their ability to target the hypoxic core of solid tumors 
that is resistant to conventional treatment [29, 30]. If 
Salmonella, a facultative anaerobic bacterium, is to be a 
successful treatment agent in anti-cancer therapy, 
then the potential problems with its toxicity to the 
host need to be resolved [8, 31]. In most cases 
attenuated forms are created and used as test 
therapeutic agents [9, 32-34]. However the mutations 
required attenuating a bacterium might also 
compromise its tumor targeting and killing ability. 
Recently, a systematic study of Salmonella mutants 
[35] partially resolved this issue by identifying several 
attenuated mutant bacteria with either mild or 
moderate reductions in tumor fitness.  
  
 
Figure 3. The percentage of body weight loss of the mice after the injection of YB1 and PBS. The green line panels belonged to the YB1 treated group, and the pink 
line panels belonged to the control group. The body weight was observed every two days. In general, the body weight loss among the YB1 treated group was more 
than that of the control group during the initial 8 days after the YB1 injection (each p<0.05), especially during the initial 6 days (each p<0.01). The p values of each time 
point were showed above.  
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Figure 4. Salmonella YB1 inhibited neuroblastoma growth in vivo. A and B, monitoring of in situ neuroblastoma growth by Xenogen IVIS 100 after SK-NLP/luciferase 
cells implantation and YB1 treatment. Fig. 5A was taken after 2 weeks of neuroblastoma implantation and before the bacterial inoculation. The upper panel was 
assigned to YB1 treatment and the lower panel represented the control group. Fig. 5B was taken 2 weeks after YB1 and PBS injection. The intensity of luciferin signals 
significantly decreased, not only at the primary tumor but also at the metastatic sites. For treated mouse 5, there was no more luciferin signal detected; C, decrease 
in tumors size of neuroblastoma after YB1 treatment. The upper panel was YB1 treated group, the lower panel was control group. The tumor is the mass detected 
on top of the 2 kidneys also shown for comparison. In general, the tumors size of the YB1 treated group was significantly smaller than that of control group. The 
tumor mass resolved completely in mouse 5; D, the mean values of tumor and kidney weight between the YB1 treated and control groups. There was statistically 
significant less tumor weight in the YB1 treated group when compared to the control group. The data were expressed as mean ± SD. *** P < 0.01. 
 
Instead of attempting to attenuate the potency of 
the Salmonella bacteria, we utilized an alternative 
approach in using genetic modified Salmonella YB1 
which make them not viable in normal tissues with 
normal oxygen gradient. YB1 was designed to survive 
and grow only under anaerobic condition to target 
hypoxic regions of solid tumor. Previously, we 
showed that YB1 can retard the growth of breast 
cancer by using nude mice model [8]. In this study, we 
demonstrated that YB1 can also retard the growth of 
neuroblastoma carried by SCID mice in addition to 
nude mouse breast cancer model tested before. The 
SCID mice have no functional B cells and T cells and 
are more immune-deficient than nude mice which 
have no functional T cells. However, YB1 still 
accumulated inside tumor and caused the tumor 
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regression in both neuroblastoma SCID/beige mice 
model and nude mice model [15] without killing the 
treated mice. This result not only further proved the 
success engineering of YB1 strain, but also indicated 
the innate immune response played an important role 
in Salmonella cancer therapy, which was demonstrated 
by our previous publication [15]. 
The TLRs are transmembrane proteins expressed 
by cells of the innate immune system, which 
recognize invading microbes and activate signaling 
pathways that launch immune and inflammatory 
responses. Recent research shows TLRs are expressed 
on a series of tumor cells, such as colon cancer, breast 
cancer, prostate cancer, melanoma, lung cancer and 
ovarian tumors [36, 37], and some of them may act as 
a double-edged sword, enhancing host immunity 
against the tumor by stimulating antigen presenting 
cells, and protecting the tumor from host surveillance 
[38-40].  
 
 
Figure 5. The expression of TLR4 and 5 under the invasion of YB1 and SL7207. A, TLR4 and TLR5 expression of neuroblastoma cells increased under anaerobic 
condition. The expression of TLR-4,5 genes on SK-NLP/luciferase cells after treated with YB1 and SL7207 under anaerobic and YB1 under aerobic conditions. The 
data were pooled from the experiments done in triplicate, and expressed as mean ± SD. ** P < 0.05; *** P < 0.01; B-E, the ICH results from the TLR4 and 5 expression 
in the tumor. TLR4 stain: B and C; TLR 5 stain: D and E; YB1 treated tumor: C and E; control: B and D. 
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Since the Salmonella typhimurium is gram 
negative bacteria with abundant LPS and flagellin, 
and TLR4 and 5 are the receptors of LPS and flagellin, 
respectively, we performed the TLR4 and 5 genes 
detect through the RT-PCR after the treatment of YB1. 
The Quantitative-PCR showed that TLR4 and 5 genes 
expressed on the SK-NLP cells, for TLR4 and 5 genes 
expression, there were significant difference between 
the group of YB1 treated under aerobic conditions and 
the group of YB1 treated under anaerobic condition 
(P<0.05, P<0.05) (Fig. 5A). The same results between 
the group of YB1 treated under normoxia and the 
group of SL 7207 treated under hypoxia (P<0.01, 
P<0.05). The result was consistent with the TLR 4 and 
5 protein expression in vivo (Fig. 5B, C, D and E). 
These results might indicate that only alive bacteria 
could induce strong innate response though TLR4 and 
5, but the dead bacteria had little effect.  
In vitro, YB1 induced about 31.4% SK-NLP cells 
apoptosis, almost the same efficacy as SL7207 (29.1%), 
and it is only 10.8% under normoxia (Fig. 1). This 
result further proved that YB1 has been successfully 
converted to an “obligate” anaerobe with removing 
the lethal toxicity of the host strain while maintaining 
its tumor invasion under hypoxia [8]. 
In vivo, YB1 showed strong infiltration into 
neuroblastoma in SCID/beige mice model, as 
evidenced by the significant count of bacteria found in 
the tumors over normal organs (P<0.01) and the 
tumors weight compared to the PBS control group 
(P<0.01). Very few YB1 cells were found in the normal 
tissues as hearts, spleens and livers, and there were no 
bacteria detected in brains, lungs, kidneys and blood 
after two weeks of YB1 treatment (Fig. 2). This is in 
sharp contrast with SL7207 treated mice where 
bacterial cells distributed with high CFU in normal 
organs, which caused the mice dead rapidly. When 
compared with untreated mice, YB1 considerably 
retarded tumor growth without affecting the survival 
of the animals except for the initial body weight loss 
(Fig. 3, Fig. 4A, 4B, 4C and 4D). 
As the expansion of the previous study [15], this 
study further demonstrated the direct killing effect of 
Salmonella under both in vitro and in vivo setting. We 
also analyzed the dynamic side-effects profile of YB1 
through survival rate, body weight loss over time, 
tissue distribution of bacteria, etc. These further 
verified the potential clinical application of YB1 in 
solid tumors. 
In conclusion, we have demonstrated that 
systemic administration of tumor targeting YB1 
induced apoptosis on neuroblastoma cells and 
resulted in tumor growth suppression. While the 
bacteria targeted at the cancer cells in the tumor core, 
it did not induce significant damage or dysfunction of 
other normal organs or tissues, as our previous report 
[8]. Therefore, our data suggested YB1 could be a 
useful tool in delivering anti-neuroblastoma agents. It 
has the potential of targeting the cancer cells at the 
hypoxic core of the tumors with a totally different 
cytotoxic mechanism comparing to conventional 
chemotherapeutic agents. These results also indicated 
that YB1 as an anticancer agent may not only specific 
to some cancer, but also could be a common weapon 
against many solid tumors. Further work is warranted 
to elucidate the underlying mechanism of tumor 
target killing effect of the genetically engineered 
anaerobic YB1. The effect of such approach in 
immune-competent mice may also warrant further 
exploration.  
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